This article is more than 5 years old. Information may no longer be current.
Voriconazole may be ‘major advance’ in fungal endophthalmitis treatment
Click Here to Manage Email Alerts
Orally administered voriconazole showed good tolerability and bioavailability in trials in noninflamed human eyes, and the drug may represent an important advance in the prophylaxis of exogenous or endogenous fungal endophthalmitis, according to a study.
Seenu Hariprasad, MD, and colleagues at the Barnes Retina Institute in St. Louis treated 14 patients undergoing pars plana vitrectomy with oral administration of two 400 mg doses of voriconazole, 12 hours apart, before surgery.
The percentages of plasma voriconazole concentration achieved in the vitreous was 38%, and in the aqueous, 53%. Mean vitreous and aqueous minimum inhibitory concentrations for 90% of isolates were achieved against a wide spectrum of yeasts and molds.
The study is published in the January issue of Archives of Ophthalmology.